Congress is looking to give the Food and Drug Administration the controversial and complex job of controlling tobacco marketing and advertising. FDA would not be able to ban cigarettes or require zero nicotine products, under legislation recently approved by a key House committee. But it would gain authority to approve cigarette labeling, limit certain promotional claims and curb marketing to minors. The measure provides legal authority for a regulatory approach devised more than 10 years ago under former FDA Commissioner David Kessler, but subsequently struck down by the courts.
Congress is looking to give the Food and Drug Administration the controversial and complex job of controlling tobacco marketing and advertising. FDA would not be able to ban cigarettes or require zero nicotine products, under legislation recently approved by a key House committee. But it would gain authority to approve cigarette labeling, limit certain promotional claims and curb marketing to minors. The measure provides legal authority for a regulatory approach devised more than 10 years ago under former FDA Commissioner David Kessler, but subsequently struck down by the courts.
Since then, a coalition of health groups, antismoking organizations and Democratic legislators have pushed for legislation to firmly establish federal control over tobacco marketing. To offset concerns raised by the Bush administration and FDA Commissioner Andrew von Eschenbach that the agency lacks the resources to take on such a heavy new burden, the bill authorizes new user fees to support the program. Tobacco companies would contribute some $85 million in the first year and increasing fees thereafter. Marlboro producer Philip Morris, part of the Altria Group, supports FDA regulation, while Reynolds American and others oppose it. Some Republicans may try to block the legislation if it moves forward. The White House has stated opposition to the measure, but President Bush might not want to veto a bill to curb smoking as he leaves Washington.
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
The ‘Healthy Immigrant Effect’ Is Alive and Well in Kidney Disease, Study Finds
April 3rd 2025Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health conditions compared with nonimmigrants. A new study adds kidney disease to the list.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen